It has been shown that CD74 regulates the repertoire of antigens presented by MHCII [14–16] and that this leads to primary engagement of CD4 and then CD8 components of the adaptive immune response, leading to tumor rejection [17–19]. The gene discussed is CD4; the disease is neoplasm.